캐나다 - 영어 - Health Canada

apotex inc - travoprost - solution - 0.003% - travoprost 0.003% - prostaglandin analogs

캐나다 - 영어 - Health Canada

teva canada limited - travoprost - solution - 0.004% - travoprost 0.004% - prostaglandin analogs

캐나다 - 영어 - Health Canada

sandoz canada incorporated - travoprost - solution - 0.004% - travoprost 0.004% - prostaglandin analogs

캐나다 - 영어 - Health Canada

apotex inc - travoprost - solution - 0.004% - travoprost 0.004% - prostaglandin analogs

캐나다 - 영어 - Health Canada

pharmascience inc - travoprost - solution - 0.004% - travoprost 0.004% - prostaglandin analogs

캐나다 - 영어 - Health Canada

mylan pharmaceuticals ulc - travoprost - solution - 0.004% - travoprost 0.004% - prostaglandin analogs

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - travoprost, quantity: 40 microgram/ml; timolol maleate, quantity: 6.8 mg/ml (equivalent: timolol, qty 5 mg/ml) - eye drops, solution - excipient ingredients: ethoxylated hydrogenated castor oil; sodium hydroxide; propylene glycol; hydrochloric acid; sodium chloride; mannitol; boric acid; purified water; polyquaternium-1 - duotrav is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension for whom single agent therapy provides insufficient intraocular pressure reduction.

미국 - 영어 - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - travoprost (unii: wj68r08kx9) (travoprost - unii:wj68r08kx9) - travatan z® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. none. risk summary there are no adequate and well-controlled studies in pregnant women to inform a drug-associated risk. in animal reproduction studies, subcutaneous (sc) administration of travoprost to pregnant mice and rats throughout the period of organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses. advise pregnant women of a potential risk to a fetus. because animal reproductive studies are not always predictive of human response, travatan z should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus. the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth defects is

이스라엘 - 영어 - Ministry of Health

novartis israel ltd - travoprost - ophthalmic solution - travoprost 0.004 %w/v - travoprost - travoprost - for the reduction of elevated intra ocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other iop lowering medications or insufficiently responsive to another iop lowering medication.

몰타 - 영어 - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - travoprost - eye drops, solution - travoprost 40 µg/ml - ophthalmologicals